GALAPAGOS NV/S (NASDAQ:GLPG) Price Target Increased to $150.00 by Analysts at HC Wainwright

GALAPAGOS NV/S (NASDAQ:GLPG) had its price objective raised by HC Wainwright to $150.00 in a research report sent to investors on Friday, March 29th. HC Wainwright currently has a positive rating on the biotechnology company’s stock.

A number of other research analysts have also issued reports on the company. BidaskClub upgraded GALAPAGOS NV/S from a hold rating to a buy rating in a research report on Friday, January 11th. ValuEngine upgraded GALAPAGOS NV/S from a hold rating to a buy rating in a research report on Friday, March 1st. Credit Suisse Group upgraded GALAPAGOS NV/S from a neutral rating to an outperform rating in a research report on Thursday, December 13th. Cantor Fitzgerald started coverage on GALAPAGOS NV/S in a research report on Wednesday, December 19th. They set an overweight rating and a $130.00 price objective for the company. Finally, Svb Leerink began coverage on GALAPAGOS NV/S in a research report on Friday, February 22nd. They set an outperform rating for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $125.83.

Shares of NASDAQ:GLPG opened at $115.43 on Friday. GALAPAGOS NV/S has a one year low of $85.00 and a one year high of $125.48. The stock has a market cap of $5.91 billion, a P/E ratio of -43.72 and a beta of 1.68.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Comerica Bank raised its stake in shares of GALAPAGOS NV/S by 6.3% in the 4th quarter. Comerica Bank now owns 3,120 shares of the biotechnology company’s stock worth $325,000 after buying an additional 185 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of GALAPAGOS NV/S by 2.7% during the fourth quarter. Macquarie Group Ltd. now owns 7,768 shares of the biotechnology company’s stock worth $713,000 after purchasing an additional 202 shares during the period. Dorsey Wright & Associates raised its position in shares of GALAPAGOS NV/S by 0.6% during the first quarter. Dorsey Wright & Associates now owns 48,591 shares of the biotechnology company’s stock worth $5,723,000 after purchasing an additional 289 shares during the period. We Are One Seven LLC acquired a new stake in shares of GALAPAGOS NV/S during the fourth quarter worth $27,000. Finally, Trexquant Investment LP acquired a new stake in shares of GALAPAGOS NV/S during the third quarter worth $256,000. 15.87% of the stock is currently owned by institutional investors.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Further Reading: What is the S&P 500 Index?

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.